GlassScriptPhysician profile
Thomas W Wagner
NPI 1669464673
$2,309.57
in general payments reported to CMS, 2019-2025
28 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $277 · 2021: $218 · 2022: $224 · 2023: $618 · 2024: $304 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.06 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Merck Sharp & Dohme LLC | $296.16 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Lilly USA, LLC | $176.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $167.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $155.47 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $144.53 | 2019-2023 | |
| Corium, LLC | $96.98 | 2022-2023 | Azstarys |
| Dexcom, INC. | $67.28 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $58.66 | 2020-2024 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $56.06 | 2020-2022 | |
| Cranial Technologies, INC | $56.01 | 2019-2023 | Doc Band |
| Corcept Therapeutics | $50.35 | 2020-2025 | Korlym |
| Amarin Pharma, INC. | $47.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.72 | 2019-2025 | Airsupra |
| Ironshore Pharmaceuticals INC. | $41.87 | 2019-2023 | Jornay Pm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.19 | 2020-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $25.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.03 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $19.01 | 2020 | |
| Exact Sciences Corporation | $16.95 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $16.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.72 | 2022 | |
| Inspire Medical Systems, INC. | $16.37 | 2025 | Inspire |
| Sobi, INC | $15.34 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.95 | 2024 | Qelbree |
| Tris Pharma INC | $14.45 | 2020 | |
| Upsher-Smith Laboratories LLC | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.